In patients who are HPV postive, and non-smokers who have a complete PET response to induction TPF at the primary site, would you still treat the primary site to full dose?

Descalating therapy in HPV+ H&N SCC is the subject of investigation in ongoing clinical trials. Some are investigating de-escalation through the systemic agent used concurrently with RT (cetuximab vs cisplatin), such as RTOG 1016. Others are looking into the reduction of RT dose based on response to...

I agree with @Dr. First Last. After induction chemo, I would recommend treating the primary and initially involved lymph nodes to 70 Gy regardless of response to chemo. There are several on-going studies and prelim data evaluating the possibility of reducing dose after induction chemo, but this data...